INNOVA CAPTAB | GROWTH & EARNINGS INFLECTION
Q1 FY27 Performance
- Revenue: ~₹471 Cr, up 34% YoY.
- EBITDA: ~₹75 Cr, up 33% YoY.
- EBITDA margin: ~16%.
- PAT: ~₹44 Cr, up 42% YoY.
- CDMO revenue: ~₹329 Cr, up 32%.
- Branded-generics revenue: ~₹142 Cr, up 39%.
- Volume growth: ~22%.
Jammu Facility | Key Growth Driver
- Q1 revenue: ~₹107 Cr.
- Current utilisation: ~25–30%.
- Mature utilisation potential: ~65–70%.
- Revenue potential at maturity: ~₹1,400 Cr.
- Facility is nearing EBITDA breakeven.
- Rising utilisation can create strong operating leverage.
Baddi Expansion
- New facility investment: ~₹150–170 Cr.
- Potential revenue: ~₹450–500 Cr.
- Provides another medium-term growth leg.
- Expansion adds capacity beyond Jammu.
CDMO & Branded Generics
- FY26 revenue: ~₹1,630 Cr.
- CDMO contribution: ~₹1,133 Cr.
- Branded-generics contribution: ~₹497 Cr.
- FY26 branded-generics growth: ~51%.
- Q1 FY27 branded-generics growth: ~39%.
- Both segments continue to grow strongly.
Sharon Bio | Turnaround Optionality
- FY26 revenue contribution: ~₹240 Cr.
- Focus on regulated markets.
- Canada, UK, Europe and Australia remain key markets.
- Sustained improvement could add earnings upside.
Margin & API Risk
- API/raw-material price changes have pass-through mechanism.
- Q1 gross-margin movement mainly reflected business mix.
- No structural pricing issue indicated.
- Margin improvement depends on product mix and utilisation.
Cash Flow & Balance Sheet
- FY26 operating cash flow: ~₹117 Cr.
- Working capital needs to be monitored.
- Jammu ramp-up will increase funding requirements.
- New capacity will also require capital.
- Normalised working-capital cycle targeted around 90 days.
Earnings Potential
- Revenue scenario: ₹2,400–2,600 Cr.
- EBITDA margin assumption: 16–17%.
- PAT scenario: ₹220–260 Cr.
- EPS scenario: ₹39–46.
- 30–35x multiple implies ₹1,170–1,610 framework.
- This is an illustrative valuation framework, not a price target.
Q2–Q3 FY27 Scorecard
- Jammu revenue moving above ₹120–130 Cr/quarter.
- Meaningful improvement in Jammu EBITDA.
- Volume growth around or above 20%.
- Continued double-digit CDMO growth.
- Sustained branded-generics growth.
- Working capital remains controlled.
- Continued improvement at Sharon Bio.
- Progress on Baddi expansion.
VALUATION
- CMP mentioned: ₹1,040.
- Trailing valuation around 40x FY26 earnings.
- Not deeply undervalued at current levels.
- Valuation becomes more reasonable if earnings compound strongly.
- Investment thesis depends on execution of the growth pipeline.
KEY THESIS
- Jammu is the primary earnings inflection point.
- Low current utilisation leaves significant operating leverage.
- Baddi provides an additional capacity-led growth opportunity.
- CDMO provides the core revenue base.
- Branded generics adds a faster-growing business.
- Sharon Bio offers turnaround optionality.
- Strong execution and cash-flow discipline remain critical.
Forwarded fromSTOCK MARKET UPDATES 📈
2
1August 26, 2026 1.7K 5
